The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Upadacitinib Meets Study Endpoints to Treat RA

Upadacitinib Meets Study Endpoints to Treat RA

July 5, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Upadacitinib (ABT-494) is an oral, once-daily JAK1 inhibitor in Phase 3 clinical trials for treating rheumatoid arthritis (RA).1 The SELECT Phase 3 trial by the manufacturer AbbVie is evaluating the treatment in more than 4,000 patients with moderate to severe RA in six different studies.

You Might Also Like
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Promising for RA in Phase 3 Study
  • Upadacitinib Promising for RA Patients
Also By This Author
  • Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis

A recent clinical trial, SELECT-NEXT, evaluated upadacitinib in patients with moderate to severe RA who do not adequately respond to treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).2 After Week 12, the study met its primary and secondary endpoints. The primary endpoints included ACR20 and low disease activity. Key secondary endpoints included ACR50, ACR70 and clinical remission. These results were achieved by patients taking 15 or 30 mg upadacitinib once daily.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For patients receiving 15 or 30 mg upadacitinib, the Week 12 results showed a 64% and 66% ACR20 response rate, respectively, compared with a 36% achievement in ACR20 for placebo-treated patients. The ACR50 response rates for upadacitinib-treated patients were 38% and 43%, respectively, vs. 15% for placebo-treated patients. And the ACR70 responses for upadacitinib-treated patients were achieved in 21% of patients treated with 15 mg and 27% of patients treated with 30 mg vs. 6% of placebo-treated patients. Overall, low disease activity was achieved in 48% of upadacitinib-treated patients receiving either dose compared with 17% of placebo-treated patients. Clinical remission was achieved by 31% of 15 mg upadacitinib-treated patients and 28% of 30 mg upadacitinib-treated patients. Only 10% of placebo-treated patients achieved clinical remission. All study endpoints were considered statistically significant (P<0.001) compared with placebo.

The safety of upadacitinib is still being evaluated. The treatment is also in Phase 3 trials for psoriatic arthritis and is being investigated to treat Crohn’s disease, ulcerative colitis and atopic dermatitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. AbbVie Inc. News release: AbbVie’s upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in phase 3 study in rheumatoid arthritis. PR Newswire. 2017 Jun 7.
  2. U.S. National Institutes of Health. A study comparing ABT-494 to placebo in subjects with rheumatoid arthritis on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) who have an inadequate response to csDMARDs alone (SELECT-NEXT). ClincalTrials.gov. 2017 Jun 29.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: JAK inhibitor, Rheumatoid Arthritis (RA), upadacitinib

You Might Also Like:
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Promising for RA in Phase 3 Study
  • Upadacitinib Promising for RA Patients
  • Rheumatology Drug Updates: Opana ER Painkiller Pulled from U.S. Market; Upadacitinib to Treat RA, and More

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)